Drug intelligence / Profile preview

HB-501

Development stage: Unknown
Lead developer: HOOKIPA Pharma
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intramuscular

Overview

HB-501 is a genetically engineered replicating viral vector based on the arenavirus lymphocytic choriomeningitis virus. It delivers HIV antigens derived from highly conserved regions of HIV type 1 (HIV-1) proteins, specifically targeting clade B variants. Developed by Hookipa Biotech, HB-501 is used in combination with HB-502 (based on Pichinde virus) as an alternating 2-vector therapy. This therapy aims to stimulate the immune system in people living with HIV who are already receiving antiretroviral treatment, enhancing their immune response against the virus.

Beyond the preview

Go deeper on HB-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-501.

Explore the full profile